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The role of the enzyme lipoprotein lipase (LPL) in
atherosclerosis is uncertain. To generate an animal
model of LPL deficiency, we targeted the LPL gene in
embryonic stem cells with a vector designed to disrupt
the COOH terminus of the protein and used these cells
to generate LPL-deficient mice. Germ line transmission
of the disrupted LPL allele was achieved with two chi-
meric males, and offspring from each of these animals
were phenotypically identical. Pups homozygous (-/- )
for LPL deficiency died within 48 h of birth with ex-
treme elevations of serum triglycerides (13,327 mg/dl)
associated with essentially absent LPL enzyme activity
in heart and carcass. Newborn heterozygous (+/-) LPL-
deficient pups had lower LPL enzyme activity and
higher triglycerides (370 versus 121 mg/dl) than wild
type (+/+) littermates. Adult heterozygotes had higher
triglycerides than wild type mice with ad libitum feed-
ing (236 mg/dl for +/- versus 88 mg/dl for +/+) and after
fasting for 4 h (98 mg/dl for +/- versus 51 for +/+) or 12
h (109 mg/dl for +/- versus 56 mg/dl for +/+). Triglycer-
ides were present as very low density lipoprotein partt-
cles and chylomicrons, but high density lipoprotein cho-
lesterol levels were not decreased in +/- animals.
Plasma heparin-releasable LPL activity was 43% lower
in +/- versus +/+ adult animals. LPL activity, mRNA,
and protein were lower in the tissues of +/- versus +/+
mice.
Homozygous LPL deficiency caused by disruption of
the COOH terminus of the enzyme is lethal in mice.
Heterozygous LPL deficiency caused by this mutation is
associated with mild to moderate hypertriglyceridemia
without affecting static HDL cholesterol levels. Het-
erozygous LPL-deficient mice could be useful for deter-
mining if hypertriglyceridemia, independently or in
combination with other discrete defects, influences
atherosclerosis.
Hypertriglyceridemia is a risk factor for coronary heart dis-
ease (1), but the biology underlying this epidemiology is ob-
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scure. Elevated triglycerides may cause vascular damage
through both direct and indirect mechanisms. Remnants of
triglyceride-rich lipoproteins may be directly atherogenic (2), a
hypothesis bolstered by the recent demonstration of triglycer-
ide-rich lipoproteins in human atherosclerotic lesions (3). Ele-
vated triglycerides might affect vascular health indirectly by
decreasing HDU cholesterol levels, by rendering LDL particles
more atherogenic, or by affecting clotting.
Defects in lipoprotein lipase (LPL) can cause hypertriglyc-
eridemia. LPL is increasingly recognized as a multifunctional
protein. In addition to hydrolyzing triglycerides in VLDL and
chylomicrons, the LPL protein may also function as an apoli-
poprotein, associating with the surface of various lipoproteins
to promote binding to the low density lipoprotein (LDL) recep-
tor-related protein/nj-macroglobulin receptor (4), LDL receptor
(5, 6), and extracellular proteoglycans (7, 8). The LPL protein
can be functionally divided into two major domains: an NH2 -
terminal domain containing the catalytically active site, and a
COOH-terminal domain (9). The latter is essential for catalytic
activity (10), binds lipoproteins (11), and is probably responsi-
ble for the LPL-mediated catabolism of triglyceride-rich li-
poproteins by the LDL receptor-related protein/oj-macroglob-
ulin receptor (12).
LPL could also impact atherogenesis independent of effects
on circulating triglycerides. Macrophages from human and rab-
bit atherosclerotic lesions express LPL (13-15), and higher
levels of macrophage LPL expression are found in inbred
strains of mice that are susceptible to atherosclerosis (16),
suggesting that local expression of LPL could promote uptake
of lipoproteins by vascular tissue (17). Thus genetic defects in
LPL could have opposing effects on atherosclerotic risk; sys-
temically decreased function could increase the concentration
of atherogenic, triglyceride-rich particles, but decreased mac-
rophage expression could decrease foam cell formation.
Human heterozygous LPL deficiency is probably common. It
has been postulated to form a subset of familial combined
hyperlipidemia (18), a very common genetic disorder associated
with vascular disease. However, heterozygous LPL deficiency
could have phenotypically different effects depending on ge-
netic and physiological backgrounds. This might explain why
some families with heterozygous LPL deficiency manifest fa-
milial hypertriglyceridemia (19), while others have lipid abnor-
malities associated with increased atherosclerotic risk (20).
Further complicating study of human heterozygous LPL defi-
1 The abbreviations used are: HDL, high density lipoprotein; LDL,
low density lipoprotein; VLDL, very low density lipoprotein; kb, kilo-
base pair(s); bp, base pairts); PCR, polymerase chain reaction; apo,
apolipoprotein.
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FIG. 1. Strategy for inactivation of
the mouse LPL gene. Schematic dia-
grams of the targeting vector, native (wild
type) mouse gene, a successfully targeted
allele, and the predicted restriction frag-
ments resulting from digestion of genomic
DNA with HindIII and Tthl11I are
shown. S represents SacI, TK represents
thymidine kinase (for negative selection
in the presence of ganciclovir), and NEG
represents the neomycin resistance cas-
sette (for positive selection with G418).
Also shown is the location of the LPL
genomic probe (spanning the intron
5/exon 6 junction) used for detection of
fragments by Southern blotting.
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ciency is the fact that detection of this disorder is difficult given
the large number of mutations in the LPL gene (21).
With a goal of generating an animal model of LPL deficiency
within a homogeneous genetic background suitable for study-
ing atherosclerosis, we have inactivated the LPL gene in mice
by homologous recombination using a targeting vector designed
to disrupt the COOH-terminal domain of the LPL protein.
EXPERIMENTAL PROCEDURES
Vector Construction and Generation of LPL-deficient Mice-An
8.3-kb SacUSau3AI genomic fragment was isolated from a AEMBL3
library constructed using Balb/c DNA (22). Restriction mapping, South-
ern blotting (with detection by oligonucleotides based on the mouse LPL
eDNA sequence in Ref. 23), and sequencing showed that this fragment
contained exons 7-10 of the mouse gene with essentially the same
structure described by Zechner et al. (24). A 1.8-kb EcoRUHindlII
fragment of the plasmid pRJ-l containing the neomycin resistance
cassette driven by the PGK promoter was inserted by blunt-end ligation
at a HindlII site in exon 8. This manipulation was shown to abolish the
HindlII site and interrupt exon 8, resulting in a predicted mouse LPL
protein disrupted following the leucine residue at position 380 as num-
bered in Ref. 23. This modified genomic clone was then inserted at the
XhoI site of a Bluescript plasmid (a gift from Fred Fiedorek, Chapel
Hill, NC) containing the 3.4-kb thymidine kinase fragment from pHSV-
106 to generate the targeting vector.
E14 ES cell electroporation, positive (using G418) and negative
(using ganciclovir) selection, and injections into the blastocysts of
C57BL/6J embryos were carried out as described (25). Chimeric (on the
basis of coat color) males were mated with C57BL/6J females to gener-
ate Fl animals, and these Fl animals were crossed with each other to
generate the mice characterized in this study.
Animal Genotyping-DNA isolated from tail (for most animals) or
liver (from recently expired animals) was subjected to Southern blotting
or PCR. For Southern blotting, 5-15 f.Lg of DNA was electrophoresed
followed by acid depurination, treatment with NaOH, and transfer
using standard techniques. Blots were probed with a random-primed
0.8-kb BamHUPvulI fragment of the mouse LPL gene spanning the 3'
end of intron 5 and the 5' end of exon 6. As expected, preliminary blots
showed that this probe did not hybridize with the targeting vector. For
PCR genotyping of potential heterozygotes, an upstream primer corre-
sponding to mouse exon 8 (5'-TTT ACA CGG AGG TGG ACA TCG GA)
and a downstream primer corresponding to a region near the 3' end of
the neomycin resistance cassette (5'-TCG CCT TCT ATC GCC TTC
TTG AC) were used in reactions containing genomic DNA and 2 mM
MgCl 2 subjected to the following cycling parameters: 5 min at 94°C for
1 cycle, and 1 min at 94 °C/2 min at 55 °C/3 min at 72°C for 30 cycles.
Mouse Housing, Handling, and Diet-Animal rooms were illumi-
nated between 7:00 a.m. and 7:00 p.m. Mice were fed a 50/50 mixture of
PicoLab rodent chow 20 and mouse chow 20 (product numbers 5053 and
5058) with a total fat content of -6.75%. Animals were weaned at 21
days of age. For blood collection via the retro-orbital plexus, animals
were lightly anesthetized with methoxyflurane. Deep anesthesia was
used for those animals subjected to exsanguination via inferior vena
cava venipuncture.
Lipid and Lipoprotein Analysis-Triglycerides, cholesterol, and
phospholipids were assayed enzymatically using commercially avail-
able kits (Wako Pure Chemical Industries, Ltd., Osaka, Japan). For
measurements of total lipids, serum was kept at 4 °C or on ice and
assayed within 2 h for triglycerides and phospholipids to decrease the
chances of endogenous hydrolysis (26). Cholesterol determinations were
generally done the following day after storing samples at -70 "C. HDL
cholesterol was measured after polyethylene glycol precipitation of apo
B-containing lipoproteins (27). For separation of lipoproteins by gel
filtration, serum samples from two animals with similar total lipids
were pooled and separated by FPLC using two Superose 6 columns in
series (28). The 50 fractions collected per condition were analyzed the
same day for triglycerides and the following day for phospholipids and
cholesterol.
Determination of LPL Enzyme Activity, mRNA, and Protein-LPL
activity was assayed as the salt-inhibitable ability of triplicate samples
to hydrolyze an emulsion containing radiolabeled triolein (29). For
postheparin plasma activity, animals were injected intraperitoneally
with 200 units of porcine heparin; 30 min later blood was collected from
the inferior vena cava. Previous studies have shown this procedure to be
suitable in mice (30). For other assays, individual tissues were flash
frozen in liquid nitrogen, weighed, and made 4% (w/v) in assay buffer
(29). For newborn pups, the heart was removed and processed, the
milk-filled stomach was removed and discarded (to prevent dilution of
radioactive emulsion by milk lipids), and the remaining carcass (minus
heart and stomach) was frozen, weighed, and homogenized in assay
buffer. For determination of LPL message, total RNA was prepared
from tissues by centrifugation in cesium chloride and mRNA was de-
tected by Northern blotting as described previously (31). For determi-
nation of LPL protein, tissue extracts were subjected to SDS-polyacryl-
amide gel electrophoresis and Western blotted, and LPL protein was
detected with chicken anti-bovine milk LPL as described (29). Each gel
included one lane loaded with purified bovine LPL as a positive control.
Statistical Information-Differences were assessed using unpaired,
two-tailed t tests unless otherwise specified. For the data shown in Fig.
4, ANOVA was specifically not used because groups contained different
numbers of animals.
RESULTS
The strategy for inactivating the mouse LPL gene is shown
in Fig. 1. The mouse LPL gene has 10 exons, 9 of which are
translated. The targeting vector contains ~3 kb of mouse DNA
upstream and ~5 kb downstream of the exon 8 HindIII site
where the neomycin resistance cassette (NEO) was inserted.
Predicted restriction fragments detected by the LPL probe
spanning the intron 5/exon 6 junction are shown at the bottom
of the figure for native and targeted genes. With HindIII, the
native fragment is 8.4 kb but the targeted fragment is 14.4 kb
since insertion of NEO abolishes the natural HindIII site in
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Neonatal mortality rates and serum lipids {or LPL-deficient mice
" Data are from the pr ogeny of the first three F1 x F 1 cross es in St.
Lou is.
b p = 0.0028 versus +/- by Fish er's exact test.
' Data a re presented as mean :!: S.E . in mgldl. For triglycerides,
cholesterol, a nd ph ospholipi ds, n = 3 for - /- , n = 12 for +/-, a nd n =
21 for +/+ . For HDL cholesterol , n = 3 for -/- , n = 6 for +/- , n = 6
for +/+.
cells contain only the 8.4-kb native fragm ent (lane 1), but
targeted clones also cont ain the 14.4-kb targete d alle le (lan es
2-4). When thi s sa me DNA was probed with a NEO cDNA
(lanes 5- 8 ), only th e 14.4-kb targeted allele was detected in
target ed clones (lanes 6- 8), consisten t with the presence of th e
NEO cassette in thi s fragm ent . Tth111I-digested DNA from
+/+ cells showed only the 10.3-kb native band (lane 9), but th e
expected 7.7-kb band is also presen t in targeted cells (lane 10).
Five male chimeric mice were gene rated using these ES cells.
Two independent chimer as transmitted the mutant allele
through the germ line , and ana lyses of progeny from each of
these animals were iden tical. The same alleles detected in ES
cells were detected in the offspring ofF l X F1 crosses (panel B ).
For HindIII , heterozygotes (+/- ) carri ed both the 8.4-kb native
and 14.4-kb mutant alleles while homozygotes (-/- ) had only
th e 14.4-kb allel e. For TthlllI , +/ - animals carried both the
10.3-kb native and 7.7-kb mu tant alleles while -/- mice had
only the 7.7-kb fragment .
Additional confirmation of authe ntic targe ting is shown in
panel C. Tail DNA from animals shown to be +/+ or +/- by
Southern blotting was subjected to PCR using an upstream
primer just 5' to the NEO insertion site in exon 8 and a
downstream primer complementary to NEO . The expected
- 600-bp band was amplified from heterozygotes (+/-, lanes 2
and 3) but not wild type animals (+ /+ , lan es 1 an d 4). Thi s
as say was subsequently used for rapid genotyping. In other
studies, confirmation of the homozygous state was also per -
formed by PCR using the primers of panel C in conjun ction
with primers (sepa rated by - 127 bp) flanking the NEO inser-
tion site in exon 8. With the lat ter primer s, wild type anima ls
showed a 127-bp band, homozygotes had a - 1.8-kb band (due
to the presence of the NEO cassette between th e primers), and
heterozygotes had both bands (data not shown).
Homozygote s were born via ble, initi ally appeared healthy,
but un iformly died within 48 h. The 100% mortali ty for this
genotype was sign ifican tly higher than dea th rate s for +/- and
+ /+ animals (Table I). Autop sy find ings from four homozygotes
(data not shown) were non specific , although atelectasis and
congestion in the lungs and hepatic congestion were seen con-
sis te ntly . There were no pancreatic abno rmali ties detected.
Also shown in Tabl e I are seru m lipid s from mice - 12 h after
bir th. Homozygotes had marked elevations of t riglycerides ,
phospholipids, and total choleste rol, but no detectable HDL
cholesterol. Thi s extreme hyperlipidemia was feeding-depend-
en t . One homozygote was kept from nursing (verified by th e
absence of milk in the stomach), and in this single animal at
the time of sacrifice lipids were: triglycerides, 296 mg/dl; cho-
lesterol, 95 mg/dl; phospholipids, 178 mg/dl. Triglycerides (p =
0.0019 ), cholesterol (p = 0.0008), an d phospholipids (p =
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exon 8. With Tth1111 , the native fra gment is 10.3 kb but th e
targeted fragment is 7.7 kb since NEO introduces a new
TthlllI I site 5' to the na tural TthlllI site.
Evid ence for correct targeting ofthe LPL gene in ES cells and
mice is shown in Fig. 2. Southern blots of ES cell DNA are
shown in panel A , blots of F1 X F1 mous e DNA are in panel B,
and results of a PCR as say using mouse tail DNA are in panel
C. For panel A , lanes 1-4 contain HindIII-digested DNA de-
tected with the LPL probe shown in Fig. 1. Wild type (+/+)
2 3 4 5 6
F IG. 2. Southern b lots a n d peR assays of correctly targeted ES
cell s a n d mice . Panel A shows representative Southern blots of ES
cells . Fift een J.lg of genomic DNA from non-electroporated ES cells
(lanes 1, 5, and 9) and correctly target ed ES cell clones (lanes 2·4 , 6- 8 ,
and 10) was digested with HindIII or Tthl11l , Southern blotted , and
det ected with the LPL prob e indicated sche matica lly in Fig. 1 (lanes
1-4, 9, a nd 10) or a NEO probe (lanes 5-8), consisting ofa BamHIIPvuII
fragmen t complementary to th e ph osphotransfer ase codin g region from
the vector pKJ-l. Correctly ta rget ed H indIII-cut DNA contained th e
pred icted 14.4-kb mutant band, wh ich hybrid ized wit h both LPL a nd
NEO pr obes. Correctly targeted Tth 11lI-cut DNA contained the pr e-
dicted 7.7-kb mu tan t ba nd (lane 10). Panel B shows DNA from wild typ e
(+/+), hete rozygous (+/-), a nd homozygous (-/-) mice a fter HindIII or
Tth11 11 digestion. As expected, heterozygotes have both mutant a nd
native alleles after digest ion with bot h enzymes wh ile homozygotes
have only the mutant a llele (14.4 kb for HindIII , 7.7 kb for Tth 11lI).
Panel C shows a PCR assay using the same DNA from the +/- mice in
panel B. Assays wer e perform ed as described under "Experimental
Procedures" using a n up stream primer complementary to exon 8 of the
mouse LPL gene and a downstream primer compleme ntary to NEO. As
expected, the pred icted - 600·bp band was seen in DNA from +/- mice
and with th e targe ti ng vector (la beled Plasmid) but not in +/+ mice or
in the negative contro l lane (labeled No DNA ).
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FIG. 3. LPL enzyme activity in the heart and carcass of neo-
natal mice. Pups were allowed to suckle and then sacrificed 12 h after
birth. Tissues (not including the milk-filled stomach) were flash-frozen
in liquid nitrogen and then thawed once for determination of LPL
enzyme activity as described under "Experimental Procedures." Data
represent means ± S.E. for 4 animals for -1-,8 animals for +1-, and
6 animals for +1+,with assays for each animal done in triplicate.
type animals at 12 h. HDL cholesterol levels were not de-
creased in +1- animals; in fact, HDL cholesterol was almost
significantly higher in +/- compared to +/+ pups (p = 0.0730).
As expected, LPL enzyme activity was decreased in +/- and
essentially absent in -/- pups (Fig. 3). For these experiments,
the heart was removed and assayed, then the carcass minus
the heart (and milk-filled stomach, as described under "Exper-
imental Procedures") was assayed separately.
Heterozygotes developed normally. Over 100 animals were
weighed at weekly intervals for the first two months oflife, and
although +/- animals tended to be slightly heavier than +/+
littermates, this difference was not significant (p = 0.5513).
Heterozygotes had higher triglycerides than wild type animals
with fasting and with ad libitum feeding (Fig. 4 and Table II).
With fasting, triglycerides were ~2-fold elevated in +/- versus
+/+ animals regardless of sex. With ad libitum feeding, the
genotype-specific differences in triglycerides were amplified
with the highest elevations seen in heterozygous LPL-deficient
females. There were no significant differences between groups
for total cholesterol or phospholipids.
The fasting data of Fig. 4 were obtained after a 12-h fast
(11:00 p.m. to 11:00 a.m.), an intervention that may represent
a considerable physiological stress in mice (32). However, a 4-h
fast (7:00 a.rn. to 11:00 a.m.) resulted in essentially the same
difference in triglycerides between +/- and +/+ animals
(Table II).
As with neonates, HDL cholesterol levels were not lower in
adult +/- animals. Ad libitum fed adults with heterozygous
LPL deficiency tended to have higher HDL cholesterols than
their +/+ littermates (118 ± 14 for +/- versus 100 ::'::: 9 for +/+,
P = 0.3339).
Lipoprotein analysis by gel filtration chromatography
showed that the increased triglycerides in heterozygous LPL-
deficient animals were due to an increase in VLDUchylomi-
DISCUSSION
We present evidence consistent with the inactivation of the
LPL gene in mice. Targeting of the LPL gene with a vector
designed to disrupt the COOH terminus of the LPL protein
results in severe hypertriglyceridemia and essentially absent
enzyme activity in homozygotes. These animals die within 2
days of birth. Heterozygotes have decreased enzyme activity
and mild to moderate hypertriglyceridemia with both feeding
and fasting. The homozygous and heterozygous states appear
to have different effects on HDL levels.
Homozygous LPL deficiency in humans causes a distinctive
phenotype, the chylomicronemia syndrome, that is not neces-
sarily lethal (33). Naturally occurring defects in LPL activity
have also been described in cats (34), mice lacking mast cells
(W/ WV mice; Ref. 35), and mice homozygous for combined
lipase deficiency (cld / cld mice; Ref. 36). Our homozygotes re-
semble cld / cld mice. Triglycerides are similar at 12 h postpar-
tum (~1O,OOO mg/dl for cld/cld, -13,000 mg/dl for LPL -/-),
and animals uniformly die within 48 h of birth. cld / cld mice
presumably die because of microinfarcts in critical organs
caused by dense packing of chylomicrons in capillaries (37), and
a similar mechanism probably operates in LPL -/- mice. The
crons (Fig. 5, top panels, fractions 1-10). Consistent with meas-
urements of HDL cholesterol by PEG precipitation, HDL
cholesterol measured by gel filtration tended to be higher in
+/- animals (middle panels, fractions 30--38). In males,
"shoulders" to the right of the VLDL triglyceride peak
(fractions 10-15) and to the left of the HDL cholesterol peak
(fractions 20--30) were consistently more prominent in
heterozygotes.
LPL enzyme activity was decreased in animals carrying one
copy of the mutant allele (Fig. 6). Activity in plasma 30 min
after the intraperitoneal injection of heparin (panel A) was 43%
lower in heterozygotes (146 ::'::: 25 /-Lmol of FFAImllh for +/-
versus 258 ::'::: 19 for +/+, n = 4 animals per genotype, p =
0.0121). This decrease was also reflected in enzyme activity
assayed in individual tissues (panel BJ. For heart, kidney,
epididymal/parametrial and inguinal adipose tissue, lung,
psoas muscle, and brain, LPL activity was consistently de-
creased in +/- versus +/+ animals. These differences were
statistically significant only for heart and kidney (both p <
0.05) due to considerable animal-to-animal variation, espe-
cially for adipose tissue. Since these experiments were per-
formed using the F2 generation representing a mixture of the
the 129/Ola and C57BU6J strains, the genetic heterogeneity of
these animals is probably a major source of the observed var-
iation in LPL enzyme activity.
There were tissue-specific differences in the magnitude of
the decrease in enzyme activity associated with the mutant
allele. For example, in multiple assays involving six different
side-by-side comparisons of age and weight-matched +/+ ver-
sus +/- animals, the decrease in heart activity was consist-
ently less than 50% (mean decrease 28.4%) while the decrease
in renal activity was consistently greater than 50% (mean
decrease 62.4%).
LPL message and protein were decreased in heterozygotes
(Fig. 7). Both the 3.6- and 3.4-kb LPL mRNA species detected
by others in mouse tissues (23) were decreased in +1- (lane 2)
compared to +/+ (lane 1) adipose tissue. Similar differences
were seen in comparisons of adipose tissue total RNA from five
different pairs of +/+ and +/- animals. A decrease in LPL
mRNA for heterozygotes was also seen in heart (not shown).
LPL protein mass was decreased in +/- (lane 4) compared to
+/+ (lane 3) adipose tissue. Similar differences were seen in
comparisons of adipose tissue protein from three different pairs










































































































FIG. 4. Serum lipids in adult mice.
Blood was obtained by retro-orbital bleed-
ing from mice at age 7-9 weeks between
10:00 a.m. and noon. Serum was assayed
immediately or stored at -70 DC for assay
within 24 h. Data from the left side of the
figure represent mice fasted for 12 h, and
data from the right side represent ad li-
bitum fed mice. +/+ indicates wild type,
and +/- indicates heterozygotes as deter-
mined by PCR genotyping of tail DNA.
Data represent means :':: S.E. for 3-8
animals per group.
TABLE II
Serum triglycerides in adult heterozygous LPL-de{icient and
wild type mice
Data are presented as mean:':: S.E. in mg/dl.
LPL +/- mice suggest that, with the exception of the LPL -/-
state, LPL activity in mice has a limited role in determining
HDL cholesterol levels.
That heterozygous LPL-deficient mice have increased tri-
glycerides seems sensible, but this result was not predictable.
In humans, 94% of young heterozygotes have normal triglycer-
ides (19) as do mice heterozygous for the cld mutation (36). The
mechanism responsible for hypertriglyceridemia in our mice,
especially with fasting, is uncertain. Mutations generally cause
gain of function, loss of function, or have dominant negative
effects. The latter class of mutation could be relevant to our
mice since active LPL is probably a dimer and one could envi-
sion an inactive but stable monomer having a prolonged dom-
inant negative effect on triglyceride metabolism. This mecha-
cld mutation affects the posttranslational processing of both
LPL and hepatic lipase (38), but the similarities between LPL
-/- and cld/cld mice suggest that LPL is the lipase most
critical for neonatal survival.
HDL cholesterol was absent from the serum of LPL -/-
mice, an expected finding since the major sources of lipid for
HDL generation are thought to be remnant cholesterol and
phospholipid from chylomicronIVLDL metabolism. Whether
apolipoprotein A-I, the major protein ofHDL, is produced nor-
mally in LPL -/- animals is unknown. These mice could be
used to determine if nascent HDL-like particles are present in
the absence of LPL activity.
In human populations, lower levels of LPL enzyme activity
are associated with lower levels ofHDL cholesterol (39). Given
this association, one might predict that the lower (but not
absent) LPL activity ofLPL +/- mice would also be associated
with lower HDL cholesterol. This was not observed. There was
no difference in HDL cholesterol between +/- and +/+ adult
mice, and levels were almost significantly higher in heterozy-
gous neonates (Table I). At least three groups have overex-
pressed human LPL in transgenic mice (40-42), and all report
decreases in triglyceride-rich lipoproteins without significant











































































FIG. 5. Separation of serum lipopro-
teins in mice by gel filtration chro-
matography. Blood was obtained from
the inferior vena cava under deep anes-
thesia as described under "Experimental
Procedures." For each profile, serum from
two ad libitum fed animals known to have
similar lipid levels was pooled and sepa-
rated using two Superose 6 columns in
series. Fifty fractions were collected, and
each was assayed for triglyceride, choles-
terol, and phospholipid content. VLDL
(which refers to both VLDL and chylomi-
crons since animals were studied in the
fed state) and HDL peaks are appropri-
ately labeled. The expected elution posi-
tion for LDL is approximately fractions
20-25. Similar results were seen in at
least two independent profiles for each
sex and genotype. e, wild type; 0,
heterozygote.
10 20 30 40 50 10 20 30 40 50
Fraction number
A B 5+/+- +/+ -300 +/- c:::::::J +1- CJ
4
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Postheparin Plasma Heart Kidney Fat ElP Fat I Lung Liver Muscle Brain
FIG. 6. LPL enzyme activity in wild type (+/+. solid bars) and heterozygous LPL-deficient (+/-. open bars) mice. For panel A, ad
libitum fed animals were injected intraperitoneally with heparin and 30 min later plasma was obtained and LPL enzyme activity assayed as
described under "Experimental Procedures." In panel A, * indicatesp = 0.0121 versus +/+; data represent the mean ± S.E. for 4 animals (2 males
and 2 females) for each genotype with plasma values for each individual animal determined in triplicate. For panel B, ad libitum fed animals
(different from the animals used in panel A) were sacrificed and tissues flash-frozen in liquid nitrogen. fat E represents epididymal or parametrial
adipose tissue, while fat I represents inguinal adipose tissue. In panel B, * indicates p < 0.05; data represent the mean ± S.E. for 6 animals (4 males
and 2 females) for each genotype with each individual tissue value determined in triplicate. Sex differences were minimal except in fat, where
epididymal/parametrial activities were 3-4-fold higher and inguinal activities were 4-6-fold higher in females than males.
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FIG. 7. LPL mRNA and protein mass in +/+ versus +/- mice.
Adipose tissue RNA was subjected to Nort hern blotti ng (lanes 1 an d 2),
an d adipose tissue protein was subjected to Western blotting (lanes 3
an d 4). For lanes 1 an d 2, 20 fJ.g of tota l RNA was separated on agarose
gels containing formaldehyde. Equa l loading and equal RNA integri ty
for each genotype was verifie d by analysis of ethidium-stained 28 and
18 S ribosomal RNA int ensities before tran sfer . The LPL message
(indicated by th e 3.6-kb and 3.4-kb markers) was detected using a
ran dom-primed mouse LPL eDNA. For lanes 3 and 4 , 1 fJ.g of protein
was separated by SDS-polyacry lami de gel electrophoresis with the
- 55-kDa LPL prot ein (visible in both lan es at the position indica ted by
the arrowhead to the righ t of lane 4 ) detected usin g an iodinated
chicken ant i-bovine LPL ant ibody. N umb ers to the left of lane 3 ind icat e
the positio ns of protein size sta ndards. Resu lts shown for LPL mRNA
are representative of comparisons of 5 different pairs of +/+ and +/-
animals . Resul ts for LPL protein are representative of comparisons of
3 differen t pair s of +/+ an d +/- animals .
1 2
apo CI probably operates through a simila r mechanism to
increase triglycerides (48). Overexpression of apo CII , a co-
factor for LPL activity, surpris ingly also increases triglycer -
ides , perhap s by inte rfering with th e ability of VLDL to bind
glycosaminoglycan s (49). Each of th ese models was genera ted
using human tran sgenes in mice. Hetero zygous LPL-d eficient
mice have the theoretical advantage of man ifesting hyp ertri-
glycer idemia that is not depend ent on th e expression of a
protein from anothe r species .
Anoth er potential advantage of our model is the lack of an
effect on HDL choles te rol levels. In species with cholesteryl
es te r tran sfer pr otein act ivity, triglyceride concentrations are
inversely related to HDL choles te rol levels, making it difficult
to decide whethe r beneficial effects on vascul ar disea se are du e
to decreased triglycerides or increase d HDL-C. LPL +/- mice
sui tably backcrossed into th e C57BU6J background could be
useful for determining how hypertriglycerid emi a alone affect s
athe roscleros is. In addition, assessing atherosclerotic disease
in LPL +/- mice in the setting of diabet es mellitus, ethanol
intak e, and hypoth yroidism , or after crossing th ese animals
with cholesteryl es te r transfer protein tran sgenic mice, with
heterozygotes for apo E deficiency , or with heterozygote s for
LDL receptor deficiency, could provide ins ight into whether












nism does not appea r to be operative in our +/- mice. LPL
activity (Fig. 6), message, and pr otein (Fig. 7) are lower in th e
tissu es of heterozygotes, making it likely th at our mutation
causes loss of functi on thro ugh a decrease in LPL protein .
Cons is tent with this hyp oth esis, COOH-terminal truncation of
human LPL at residue 381, essentially the sa me site disrupted
in mouse LPL in th e current study, cau ses a loss of catalytic
activity as well as a decrease in protein mass in transien t
tran sfection studies (43). Thus, the phenotype of mice gener-
ated by COOH-te rmina l disruption of LPL may be simila r to
th e phen otype genera ted by targeting regions of th e LPL gene
5' to th e exon 8 site chosen in this study.
Why th en do LPL +/- mice have elevated tri glycerides in the
fasted state on a low fat diet? At least four expla na t ions are
possible. First , the disruption of the COOH terminus of th e
LPL molecul e could somehow impair th e metabolism oftriglyc-
eride-ri ch lipoprotein s as sugges ted by cell culture studies (12).
We do not find evidence of a protein with altered size in +/-
ti ssues to support this hypoth esis, bu t Western blots were done
with a single antibody, rai sing th e possibility th at an alte red
pr otein is produced but not recogn ized by our an tib ody. Second,
LPL deficiency could affect triglyceride-rich particle composi-
t ion and impair clearanc e. Third, LPL deficiency could reduc e
hepatic reuptak e of apo B-containing particles with a net effect
of lipoprotein overproduct ion by the liver (44). Our enzyme
assay was not sufficiently sens itive to detect LPL activity in
mouse liver, although we have been able to det ect very low
levels of LPL protein in th is tissue by Western blotting (not
shown). Fourth, LPL deficiency is like ly to increase th e concen-
tration of remnan t particles in these anima ls, a possibility
suggested by the "shoulders " of particles seen to the right of the
tr iglyceride peak and to the left of th e cholesterol peak for
males in Fig. 5. Remnants are noncompetiti ve inhibitors ofLPL
activity, and even low concentrations of these particles could
subs ta nt ially interfere with VLDL hydrolysis (45).
There are oth er mou se model s of elevate d triglycerides.
Overexpression of apo CII I in mice results in hypertriglyceri -
demia (46). Thi s condit ion is corrected by overexpression of apo
E (47), supporti ng th e hypoth esis that excess apo CII I displaces
apo E from triglyceride-ri ch lipoproteins , thereby hindering
clearance by apo E-depend en t mechanisms. Overexpression of
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